169 related articles for article (PubMed ID: 26530375)
1. The Actual Role of Receptors as Cancer Markers, Biochemical and Clinical Aspects: Receptors in Breast Cancer.
Brennan M; Lim B
Adv Exp Med Biol; 2015; 867():327-37. PubMed ID: 26530375
[TBL] [Abstract][Full Text] [Related]
2. Biomarkers for personalized oncology: recent advances and future challenges.
Kalia M
Metabolism; 2015 Mar; 64(3 Suppl 1):S16-21. PubMed ID: 25468140
[TBL] [Abstract][Full Text] [Related]
3. Validated biomarkers: The key to precision treatment in patients with breast cancer.
Duffy MJ; O'Donovan N; McDermott E; Crown J
Breast; 2016 Oct; 29():192-201. PubMed ID: 27521224
[TBL] [Abstract][Full Text] [Related]
4. Breast Cancer Biomarkers: Challenges in Routine Estrogen Receptor, Progesterone Receptor, and HER2/neu Evaluation.
Jorns JM
Arch Pathol Lab Med; 2019 Dec; 143(12):1444-1449. PubMed ID: 31373514
[TBL] [Abstract][Full Text] [Related]
5. [Hormonal Receptor and HER2 Analyses for Breast Cancer Using Cell Blocks in Routine Work: Experience at Our Institution].
Nishimura R
Rinsho Byori; 2015 Mar; 63(3):319-21. PubMed ID: 26524854
[TBL] [Abstract][Full Text] [Related]
6. HER2 status in elderly women with breast cancer.
Laird-Fick HS; Gardiner JC; Tokala H; Patel P; Wei S; Dimitrov NV
J Geriatr Oncol; 2013 Oct; 4(4):362-7. PubMed ID: 24472480
[TBL] [Abstract][Full Text] [Related]
7. Assessment of molecular markers of clinical sensitivity to single-agent taxane therapy for metastatic breast cancer.
Van Poznak C; Tan L; Panageas KS; Arroyo CD; Hudis C; Norton L; Seidman AD
J Clin Oncol; 2002 May; 20(9):2319-26. PubMed ID: 11981003
[TBL] [Abstract][Full Text] [Related]
8. [Molecular characterization of breast cancer in clinical practice].
Zemmouri Y; De Croze D; Vincent Salomon A; Rouzier R; Bonneau C
Gynecol Obstet Fertil; 2016 May; 44(5):285-92. PubMed ID: 27150068
[TBL] [Abstract][Full Text] [Related]
9. Alteration of immunohistochemical biomarkers between pre- and post-chemotherapy: hormone receptors, HER2 and Ki-67.
Kumaki N; Umemura S; Tang X; Saito Y; Suzuki Y; Tokuda Y
Breast Cancer; 2011 Apr; 18(2):98-102. PubMed ID: 21290265
[TBL] [Abstract][Full Text] [Related]
10. [Prognostic and predictive factors in breast cancer].
Bozhok AA; Semiglazov VF; Semiglazov VV; Arzumanov AS; Klettsel' AE
Vopr Onkol; 2005; 51(4):434-43. PubMed ID: 16308974
[TBL] [Abstract][Full Text] [Related]
11. Distribution and prognosis of molecular breast cancer subtypes defined by immunohistochemical biomarkers in a Spanish population-based study.
Puig-Vives M; Sánchez MJ; Sánchez-Cantalejo J; Torrella-Ramos A; Martos C; Ardanaz E; Chirlaque MD; Perucha J; Díaz JM; Mateos A; Machón M; Marcos-Gragera R
Gynecol Oncol; 2013 Sep; 130(3):609-14. PubMed ID: 23747837
[TBL] [Abstract][Full Text] [Related]
12. Ribociclib in HR-positive, HER2-negative breast cancer.
Burki TK
Lancet Oncol; 2016 Nov; 17(11):e482. PubMed ID: 27746106
[No Abstract] [Full Text] [Related]
13. A bad tumor biomarker is as bad as a bad drug: The gap between genomics data and phenotype to predict response.
Viale G
Breast; 2015 Nov; 24 Suppl 2():S23-5. PubMed ID: 26255744
[TBL] [Abstract][Full Text] [Related]
14. Oncotype DX test on unequivocally HER2-positive cases: potential for harm.
Bhargava R; Dabbs DJ
J Clin Oncol; 2012 Feb; 30(5):570-1. PubMed ID: 22231038
[No Abstract] [Full Text] [Related]
15. Comparison of the expression of prognostic biomarkers between primary tumor and axillary lymph node metastases in breast cancer.
Zhao S; Xu L; Liu W; Lv C; Zhang K; Gao H; Wang J; Ma R
Int J Clin Exp Pathol; 2015; 8(5):5744-8. PubMed ID: 26191291
[TBL] [Abstract][Full Text] [Related]
16. [Biological features of breast cancer in patients under 35].
Damenia AO; Turkevich EA; Semiglazov VF; Kochetova IA; Gurbanov SS; Bit-Sava EM; Efimenko AV
Vopr Onkol; 2007; 53(6):674-6. PubMed ID: 18416136
[TBL] [Abstract][Full Text] [Related]
17. Predictive markers in breast cancer: An update on ER and HER2 testing and reporting.
Calhoun BC; Collins LC
Semin Diagn Pathol; 2015 Sep; 32(5):362-9. PubMed ID: 25770732
[TBL] [Abstract][Full Text] [Related]
18. Immunohistochemical analysis of estrogen and progesterone receptor and neu expression in breast carcinoma.
Chu JS; Lee WJ; Chen KM; Hsu HC
J Formos Med Assoc; 1994 Apr; 93(4):277-82. PubMed ID: 7914767
[TBL] [Abstract][Full Text] [Related]
19. Utility of estrogen receptor, progesterone receptor, and HER-2/neu analysis of multiple foci in multifocal ipsilateral invasive breast carcinoma.
East EG; Pang JC; Kidwell KM; Jorns JM
Am J Clin Pathol; 2015 Dec; 144(6):952-9. PubMed ID: 26573003
[TBL] [Abstract][Full Text] [Related]
20. Clinical Notice for American Society of Clinical Oncology-College of American Pathologists guideline recommendations on ER/PgR and HER2 testing in breast cancer.
Hammond ME; Hayes DF; Wolff AC
J Clin Oncol; 2011 May; 29(15):e458. PubMed ID: 21502545
[No Abstract] [Full Text] [Related]
[Next] [New Search]
